-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Rr3gG67QeDmspGHYgifVHVmLD8e7xqsV3NdD3LMX4DNSDxK77F8HOrWUjmMrmpEl zi0+UtYpF9uDkNRtbb671Q== 0000950123-09-015914.txt : 20090622 0000950123-09-015914.hdr.sgml : 20090622 20090622165011 ACCESSION NUMBER: 0000950123-09-015914 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20090622 DATE AS OF CHANGE: 20090622 GROUP MEMBERS: ARGERIS KARABELAS GROUP MEMBERS: CDC IV, LLC GROUP MEMBERS: CDC OPERATIONS LLC GROUP MEMBERS: DAVID R. RAMSAY GROUP MEMBERS: JAN LESCHLY SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-57907 FILM NUMBER: 09903742 BUSINESS ADDRESS: STREET 1: 801 CORPORATE CENTER DRIVE STREET 2: SUITE 210 CITY: RALEIGH STATE: NC ZIP: 27607 BUSINESS PHONE: 919 582 9050 MAIL ADDRESS: STREET 1: 801 CORPORATE CENTER DRIVE STREET 2: SUITE 210 CITY: RALEIGH STATE: NC ZIP: 27607 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CDC IV LLC CENTRAL INDEX KEY: 0001365385 IRS NUMBER: 204153867 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 47 HULFISH STREET STREET 2: SUITE 310 CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: 609-683-8300 MAIL ADDRESS: STREET 1: 47 HULFISH STREET STREET 2: SUITE 310 CITY: PRINCETON STATE: NJ ZIP: 08542 SC 13D/A 1 c87131sc13dza.htm SCHEDULE 13D - AMENDMENT NO. 4 Schedule 13D - Amendment No. 4

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 4 )*

BioDelivery Sciences International, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
09060J106
(CUSIP Number)
David R. Ramsay
CDC IV, LLC
47 Hulfish Street, Suite 310
Princeton, New Jersey 08542
(609) 683-8300
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
June 15, 2009
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 

                     
CUSIP No.
  
09060J106  
  

 

           
1   NAMES OF REPORTING PERSONS

CDC IV, LLC
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  Not Applicable.
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   3,626,115
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH 10   SHARED DISPOSITIVE POWER
     
    3,626,115
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,626,115 shares of common stock comprised of: (i) a warrant to purchase 601,120 shares of the Issuer’s common stock, issued in February 2006; (ii) 1,120,995 shares of the Issuer’s common stock and a warrant to purchase 904,000 shares of the Issuer’s common stock, issued in May 2006; and (iii) a warrant to purchase 1,000,000 shares of Issuer’s common stock, issued March 2007.
     
12   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  16.7%
     
14   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  OO

2

 

                     
CUSIP No.
  
09060J106  
  

 

           
1   NAMES OF REPORTING PERSONS

CDC Operations LLC
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  Not Applicable.
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   3,626,115
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH 10   SHARED DISPOSITIVE POWER
     
    3,626,115
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,626,115 shares of common stock comprised of: (i) a warrant to purchase 601,120 shares of the Issuer’s common stock, issued in February 2006; (ii) 1,120,995 shares of the Issuer’s common stock and a warrant to purchase 904,000 shares of the Issuer’s common stock, issued in May 2006; and (iii) a warrant to purchase 1,000,000 shares of Issuer’s common stock, issued March 2007.
     
12   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  16.7%
     
14   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  OO

3

 

                     
CUSIP No.
  
09060J106 
  

 

           
1   NAMES OF REPORTING PERSONS

David R. Ramsay
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  Not Applicable.
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America
       
  7   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   3,626,115
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH 10   SHARED DISPOSITIVE POWER
     
    3,626,115
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,626,115 shares of common stock comprised of: (i) a warrant to purchase 601,120 shares of the Issuer’s common stock, issued in February 2006; (ii) 1,120,995 shares of the Issuer’s common stock and a warrant to purchase 904,000 shares of the Issuer’s common stock, issued in May 2006; and (iii) a warrant to purchase 1,000,000 shares of Issuer’s common stock, issued March 2007.
     
12   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  16.7%
     
14   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN

4

 

                     
CUSIP No.
  
09060J106 
  

 

           
1   NAMES OF REPORTING PERSONS

Argeris Karabelas
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  Not Applicable.
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America
       
  7   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   3,626,115
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH 10   SHARED DISPOSITIVE POWER
     
    3,626,115
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,626,115 shares of common stock comprised of: (i) a warrant to purchase 601,120 shares of the Issuer’s common stock, issued in February 2006; (ii) 1,120,995 shares of the Issuer’s common stock and a warrant to purchase 904,000 shares of the Issuer’s common stock, issued in May 2006; and (iii) a warrant to purchase 1,000,000 shares of Issuer’s common stock, issued March 2007.
     
12   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  16.7%
     
14   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN

5

 

                     
CUSIP No.
  
09060J106 
  

 

           
1   NAMES OF REPORTING PERSONS

Jan Leschly
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   o 
     
3   SEC USE ONLY
   
   
     
4   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  Not Applicable.
     
5   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America
       
  7   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   3,626,115
       
EACH 9   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH 10   SHARED DISPOSITIVE POWER
     
    3,626,115
     
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,626,115 shares of common stock comprised of: (i) a warrant to purchase 601,120 shares of the Issuer’s common stock, issued in February 2006; (ii) 1,120,995 shares of the Issuer’s common stock and a warrant to purchase 904,000 shares of the Issuer’s common stock, issued in May 2006; and (iii) a warrant to purchase 1,000,000 shares of Issuer’s common stock, issued March 2007.
     
12   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  16.7%
     
14   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN

6

 

EXPLANATORY NOTE
This Amendment No. 4 to the Schedule 13D amends and supplements Items 4, 5, 6 and 7 of the Schedule 13D, filed June 12, 2006, by CDC IV, LLC, a Delaware limited liability company (“CDC IV”) relating to the Common Stock, $0.001 par value per share, of BioDelivery Sciences International, Inc., a Delaware corporation (the “Issuer”); Amendment No. 1 to the Schedule 13D, filed August 22, 2006, by CDC IV relating to the Common Stock, $0.001 par value per share, of Issuer, Amendment No. 2 to the Schedule 13D, filed September 1, 2006, by CDC IV relating to the Common Stock, $0.001 par value per share, of Issuer and Amendment No. 3 to the Schedule 13D filed March 16, 2007, by CDC IV relating to the Common Stock, $0.001 par value per share, of Issuer.
Item 4. Purpose of Transaction.
The response to Item 4 of the Schedule 13D is hereby amended to add the following information:
“On June 15, 2009, June 16, 2009, June 17, 2009, June 18, 2009, and June 19, 2009, CDC IV sold an aggregate of 879,005 shares of Common Stock at prices ranging from $6.3000 to 8.4002 per share, as set forth on Exhibit 99.1 incorporated by reference herein and attached hereto. CDC IV will continue to review its investment in the Issuer and may determine, based on market and general economic conditions, the market price of the Issuer’s shares of Common Stock and other factors deemed relevant by CDC IV, to acquire or dispose of additional shares of Common Stock.”
Item 5. Interest in Securities of the Issuer.
The response to Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:
“(a) As of the date of this Amendment, giving effect to the dispositions described in Item 4, CDC IV is the beneficial owner of 3,626,115 shares of the Issuer’s Common Stock, consisting of (i) a warrant to purchase 601,120 shares of the Issuer’s Common Stock, issued in February 2006; (ii) 1,120,995 shares of the Issuer’s Common Stock and a warrant to purchase 904,000 shares of the Issuer’s Common Stock, issued in May 2006; and (iii) a warrant to purchase 1,000,000 shares of Issuer’s Common Stock, issued March 2007, representing 16.7% of the Issuer’s shares of Common Stock outstanding (based upon 19,232,812 shares of Common Stock outstanding, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009). As the manager of CDC IV, CDC Operations and David R. Ramsay, Argeris Karabelas and Jan Leschly, the Partners of CDC Operations, may be deemed the beneficial owner of the shares of the Issuer’s Common Stock held by CDC IV. CDC Operations and Messrs. Ramsay, Karabelas and Leschly each disclaims beneficial ownership of the securities and this report shall not be deemed an admission that any of Messrs. Ramsay, Karabelas and Leschly or CDC Operations is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein.
(b) By virtue of its status as manager of CDC IV, CDC Operations and David R. Ramsay, Argeris Karabelas and Jan Leschly, as Partners of CDC Operations and the individuals with voting and dispositive power of the securities held by CDC IV, may be deemed to share voting and dispositive power with CDC IV with respect to the 3,626,115 shares of the Issuer’s Common Stock held by CDC IV. CDC Operations and Messrs. Ramsay, Karabelas and Leschly each disclaims beneficial ownership of the securities and this report shall not be deemed an admission that any of Messrs. Ramsay, Karabelas and Leschly or CDC Operations is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein.
(c) During the past sixty days prior to the date hereof, neither CDC IV, CDC Operations, David R. Ramsay, Argeris Karabelas nor Jan Leschly, nor, to the knowledge of each of the above, any executive officer, director or managing member of CDC IV or CDC Operations, has engaged in any transaction in the Issuer’s Common Stock, with the exception of the transactions described above in Item 4.
(d) No person, other than CDC IV, CDC Operations, David R. Ramsay, Argeris Karabelas and Jan Leschly, is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by CDC IV.
(e) Not applicable.”

 

 

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
The response to Item 6 of the Schedule 13D is hereby amended to add the following information:
“On June 4, 2009, CDC Operations, the manager of CDC IV, delegated to Manchester Securities Corp., a wholly owned subsidiary of Elliott Associates L.P., all of CDC IV’s rights and authority with respect to the investment decisions relating to the Common Stock and the warrants to acquire Common Stock of the Issuer owned of record by CDC IV.”
Item 7. Material to be Filed as Exhibits.
     
Exhibit   Description
 
    
99.1
  Description of sales of Common Stock of BioDelivery Sciences International, Inc. by CDC IV, LLC from June 15, 2009 to June 19, 2009.

 

 

 

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. The undersigned hereby express our agreement that this Schedule 13D/A is filed on behalf of each of us pursuant to Rule 13d-1(k) under the Securities Exchange Act.
         
Dated: June 22, 2009  CDC IV, LLC
 		  
  By:   /s/ David R. Ramsay    
    Name:   David R. Ramsay   
    Title:   Authorized Signatory   
 
Dated: June 22, 2009  CDC OPERATIONS LLC
 		  
  By:   /s/ David R. Ramsay    
    Name:   David R. Ramsay   
    Title:   Authorized Signatory   
     
Dated: June 22, 2009  /s/ David R. Ramsay    
  David R. Ramsay   
     
Dated: June 22, 2009  /s/ Argeris Karabelas    
  Argeris Karabelas   
     
Dated: June 22, 2009   /s/ Jan Leschly    
  Jan Leschly   
     
 
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations
(See 18 U.S.C. 1001)

 

 

 

EXHIBIT INDEX
     
Exhibit   Description
 
    
99.1
  Description of sales of Common Stock of BioDelivery Sciences International, Inc. by CDC IV, LLC from June 15, 2009 to June 19, 2009.

 

 

EX-99.1 2 c87131exv99w1.htm EXHIBIT 99.1 Exhibit 99.1
Exhibit 99.1
                         
                    Where and how the
    Amount of           transaction was
Date of Transaction   Securities Sold   Price Per Share   effected
06/15/09
     39,263     $ 6.9000     Open Market
06/15/09
     400     $ 6.9050     Open Market
06/15/09
     100     $ 6.9100     Open Market
06/15/09
     3,527     $ 6.9200     Open Market
06/15/09
     423     $ 6.9300     Open Market
06/15/09
     2,777     $ 6.9400     Open Market
06/15/09
     5,100     $ 6.9500     Open Market
06/15/09
     4,500     $ 6.9600     Open Market
06/15/09
     200     $ 6.9650     Open Market
06/15/09
     100     $ 6.9700     Open Market
06/15/09
     11,600     $ 6.9800     Open Market
06/15/09
     100     $ 6.9900     Open Market
06/15/09
     31,694     $ 7.0000     Open Market
06/15/09
     2,900     $ 7.0050     Open Market
06/15/09
     5,100     $ 7.0100     Open Market
06/15/09
     500     $ 7.0120     Open Market
06/15/09
     300     $ 7.0125     Open Market
06/15/09
     5,100     $ 7.0200     Open Market
06/15/09
     2,800     $ 7.0300     Open Market
06/15/09
     11,800     $ 7.1000     Open Market
06/15/09
     5,988     $ 7.1100     Open Market
06/15/09
     800     $ 7.1200     Open Market
06/15/09
     100     $ 7.1300     Open Market
06/15/09
     27,699     $ 7.2000     Open Market
06/15/09
     1,300     $ 7.2050     Open Market
06/15/09
     300     $ 7.2075     Open Market
06/15/09
     3,779     $ 7.2100     Open Market
06/15/09
     300     $ 7.2175     Open Market
06/15/09
     1,700     $ 7.2200     Open Market
06/15/09
     1,000     $ 7.2250     Open Market
06/15/09
     5,900     $ 7.2275     Open Market
06/15/09
     1,951     $ 7.2300     Open Market
06/15/09
     400     $ 7.2350     Open Market
06/15/09
     1,000     $ 7.2400     Open Market

 

 

 

                         
                    Where and how the
    Amount of           transaction was
Date of Transaction   Securities Sold   Price Per Share   effected
06/15/09
     2,000     $ 7.2475     Open Market
06/15/09
     1,400     $ 7.2500     Open Market
06/15/09
     85,586     $ 7.5000     Open Market
06/15/09
     500     $ 7.5075     Open Market
06/15/09
     18,968     $ 7.5100     Open Market
06/15/09
     300     $ 7.5150     Open Market
06/15/09
     600     $ 7.5175     Open Market
06/15/09
     8,100     $ 7.5200     Open Market
06/15/09
     200     $ 7.5250     Open Market
06/15/09
     3,170     $ 7.5300     Open Market
06/15/09
     680     $ 7.5400     Open Market
06/15/09
     100     $ 7.5450     Open Market
06/15/09
     7,459     $ 7.5500     Open Market
06/15/09
     100     $ 7.5550     Open Market
06/15/09
     3,400     $ 7.5800     Open Market
06/15/09
     12,030     $ 7.6000     Open Market
06/15/09
     8,650     $ 7.6100     Open Market
06/15/09
     100     $ 7.6200     Open Market
06/15/09
     700     $ 7.6300     Open Market
06/15/09
     800     $ 7.6400     Open Market
06/15/09
     10,800     $ 7.6500     Open Market
06/15/09
     4,100     $ 7.6600     Open Market
06/15/09
     300     $ 7.6800     Open Market
06/15/09
     70     $ 7.6900     Open Market
06/15/09
     300     $ 7.7550     Open Market
06/15/09
     50     $ 7.7575     Open Market
06/15/09
     1,550     $ 7.7800     Open Market
06/15/09
     1,200     $ 7.7900     Open Market
06/15/09
     1,600     $ 7.7950     Open Market
06/15/09
     21,563     $ 7.8000     Open Market
06/15/09
     300     $ 7.8050     Open Market
06/15/09
     400     $ 7.8070     Open Market
06/15/09
     300     $ 7.8075     Open Market
06/15/09
     9,350     $ 7.8100     Open Market
06/15/09
     500     $ 7.8200     Open Market

 

 

 

                         
                    Where and how the
    Amount of           transaction was
Date of Transaction   Securities Sold   Price Per Share   effected
06/15/09
     1,500     $ 7.8250     Open Market
06/15/09
     1,150     $ 7.8275     Open Market
06/15/09
     1,500     $ 7.8300     Open Market
06/15/09
     2,750     $ 7.8325     Open Market
06/15/09
     4,200     $ 7.8400     Open Market
06/15/09
     700     $ 7.8450     Open Market
06/15/09
     200     $ 7.8475     Open Market
06/15/09
     1,327     $ 7.8500     Open Market
06/15/09
     3,100     $ 7.8600     Open Market
06/15/09
     100     $ 7.8650     Open Market
06/15/09
     2,230     $ 7.8675     Open Market
06/15/09
     800     $ 7.8700     Open Market
06/15/09
     1,950     $ 7.8900     Open Market
06/15/09
     7,470     $ 7.8950     Open Market
06/15/09
     2,000     $ 7.8975     Open Market
06/15/09
     1,810     $ 7.9000     Open Market
06/15/09
     600     $ 7.9300     Open Market
06/15/09
     850     $ 8.2500     Open Market
06/15/09
     10,000     $ 8.2900     Open Market
06/15/09
     4,036     $ 8.4002     Open Market
06/16/09
     23,020     $ 6.3000     Open Market
06/16/09
     1,980     $ 6.3100     Open Market
06/16/09
     29,675     $ 6.3500     Open Market
06/16/09
     200     $ 6.3600     Open Market
06/16/09
     5,400     $ 6.3700     Open Market
06/16/09
     12,949     $ 6.3800     Open Market
06/16/09
     1,776     $ 6.4000     Open Market
06/16/09
     25,000     $ 6.4500     Open Market
06/16/09
     911     $ 6.4800     Open Market
06/16/09
     14,589     $ 6.5000     Open Market
06/16/09
     400     $ 6.5100     Open Market
06/16/09
     28,148     $ 6.6000     Open Market
06/16/09
     10,290     $ 6.6200     Open Market
06/16/09
     4,651     $ 6.6500     Open Market
06/16/09
     8,911     $ 7.0000     Open Market

 

 

 

                         
                    Where and how the
    Amount of           transaction was
Date of Transaction   Securities Sold   Price Per Share   effected
06/16/09
     100     $ 7.0100     Open Market
06/16/09
     1,000     $ 7.0200     Open Market
06/17/09
     69,064     $ 6.3500     Open Market
06/17/09
     1,600     $ 6.3600     Open Market
06/17/09
     9,825     $ 6.4000     Open Market
06/17/09
     1,500     $ 6.4300     Open Market
06/17/09
     100     $ 6.4400     Open Market
06/17/09
     16,511     $ 6.6000     Open Market
06/17/09
     1,400     $ 6.6500     Open Market
06/18/09
     15,191     $ 6.4000     Open Market
06/18/09
     2,800     $ 6.4100     Open Market
06/18/09
     500     $ 6.4200     Open Market
06/18/09
     25,000     $ 6.5000     Open Market
06/18/09
     19,900     $ 6.6000     Open Market
06/19/09
     19,370     $ 6.5000     Open Market
06/19/09
     2,578     $ 6.5050     Open Market
06/19/09
     400     $ 6.5075     Open Market
06/19/09
     17,395     $ 6.5100     Open Market
06/19/09
     600     $ 6.5150     Open Market
06/19/09
     600     $ 6.5175     Open Market
06/19/09
     3,964     $ 6.5200     Open Market
06/19/09
     1,500     $ 6.5250     Open Market
06/19/09
     12,612     $ 6.5300     Open Market
06/19/09
     100     $ 6.5350     Open Market
06/19/09
     6,931     $ 6.5400     Open Market
06/19/09
     8,150     $ 6.5500     Open Market
06/19/09
     800     $ 6.5550     Open Market
06/19/09
     2,935     $ 6.5600     Open Market
06/19/09
     200     $ 6.5675     Open Market
06/19/09
     3,933     $ 6.5700     Open Market
06/19/09
     1,900     $ 6.5750     Open Market
06/19/09
     600     $ 6.5775     Open Market
06/19/09
     10,232     $ 6.5800     Open Market
06/19/09
     2,400     $ 6.5900     Open Market
06/19/09
     300     $ 6.5950     Open Market

 

 

 

                         
                    Where and how the
    Amount of           transaction was
Date of Transaction   Securities Sold   Price Per Share   effected
06/19/09
     9,314     $ 6.6000     Open Market
06/19/09
     2,400     $ 6.6100     Open Market
06/19/09
     900     $ 6.6200     Open Market
06/19/09
     100     $ 6.6225     Open Market
06/19/09
     100     $ 6.6300     Open Market
06/19/09
     300     $ 6.6500     Open Market

 

 

-----END PRIVACY-ENHANCED MESSAGE-----